If confirmed by future prospective, randomised, controlled studies (such as ALTTO or APHINITY) this RPPA-based gene expression signature could be used to direct the rationale for adjuvant treatment and research in HER2-positive breast cancer. Here, ERBB2 is linked to breast cancer.